Rakuten, Progressive and GV-backed online lending platform developer floated at the bottom of its range before a first-day pop.

Pfizer Ventures-backed cancer drug developer BioAtla's shares popped on its first day of trading yesterday following a $189m initial public offering.

The mobile commerce platform developer priced its initial public offering at the top of its range, with JD.com set to exit in the flotation.

Shares in the antibody discovery platform developer, advancing UBC research, opened at more than three times their IPO price to net it a valuation topping $15bn.

The Eli Lilly-backed antibody discovery platform developer's shares opened at more than three times their IPO price to net it a valuation topping $15bn.

The Alphabet-backed accommodation marketplace priced its initial public offering well above its range in the second huge flotation this week, to secure a $47bn valuation.

SoftBank Vision Fund is the largest investor in the food delivery service, which has priced an upsized initial public offering roughly doubling its valuation six months ago.

The underwriters have taken up the over-allotment option in BMS and Celgene-backed oncology drug developer Silverback's initial public offering.

ETH Zurich-founded HeiQ chose the London Stock Exchange for its listing having posted a $10.9m operating profit for the first half of the year.

The ByteDance-backed learning software and tutoring services provider priced its shares in the middle of their range as it went public in the US.